Pennsylvania Senator Bob Casey has come under scrutiny for his investments in Chinese pharmaceutical companies, including a fentanyl manufacturer, despite criticizing his opponent for similar investments. Casey's financial disclosures reveal that he owns stock in Humanwell, a Chinese company producing medical-grade opiates, through mutual funds such as the Massachusetts College Portfolio managed by Fidelity.
In response to Casey's ad attacking Republican candidate Dave McCormick for investing in Humanwell, McCormick accused Casey of hypocrisy and highlighted the worsening fentanyl crisis in the U.S. According to the Drug Enforcement Administration (DEA), illicit fentanyl, often manufactured in foreign labs and smuggled through Mexico, is a major contributor to the rise in overdose deaths.
Pennsylvania, a crucial state in the upcoming 2024 election, has been grappling with a significant increase in drug overdose deaths. In 2022, the state recorded 5,169 deaths from drug overdoses, ranking 14th highest in the country. The issue of substance abuse has become a focal point in the Senate race between Casey and McCormick.
Despite Casey's lead in recent polls, McCormick has pushed back against the accusations, stating that he has never invested in illegal fentanyl manufacturers. He criticized Casey for failing to address border security effectively and for spreading misinformation.
The Pennsylvania Senate seat is considered 'Lean Democratic' for the 2024 election, with Casey currently holding a lead over McCormick among likely and registered voters. The race is expected to be closely watched, given the state's potential impact on the presidential election and Senate control.
